Advertisement

Topics

OpportunityAnalyzer: NASH Opportunity Analysis and Forecasts to 2026 [Report Updated: 08052017] Prices from USD $10995

01:43 EDT 19 Aug 2017 | BioPortfolio Reports

OpportunityAnalyzer: NASH Opportunity Analysis and Forecasts to 2026

Summary

First described in 1980, nonalcoholic steatohepatitis NASH ICD10CM = K75.81 is a condition that develops as a subgroup of nonalcoholic fatty liver disease NAFLD when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides steatosis in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and it is therefore a potentially fatal condition.

GlobalData estimates the 2016 sales for the NASH market at approximately $618m across the 7MM, encompassing the US, the five major European Union countries 5EU: France, Germany, Italy, Spain, and UK, and Japan. Over the course of the 10year forecast period, the NASH market will grow at a Compound Annual Growth Rate CAGR of 45.0% across the 7MM. The US and Japanese markets are both anticipated to grow significantly, recording CAGRs of 48.1% and 50.7%, respectively, while the 5EU will record a CAGR of 30.6%. At the end of 2026, the US will account for around 88% of global sales, while the 5EU and Japan will account for around 10% and 2% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of NASH in the region, as well as the launch of more pipeline agents in this region.

Key Questions Answered

How will the NASH market landscape in the 7MM US, France, Germany, Italy, Spain, UK and Japan change from 20162026?
What are the most promising latestage pipeline drugs in NASH?
How do the clinical and commercial attributes of latestage pipeline therapies compare with one another, and against existing treatment options?
What are the greatest unmet needs in NASH? Will the pipeline drugs fulfil these needs of the market?
What are the biggest opportunities in the NASH landscape?

Scope

Overview of NASH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline NASH market revenue from 20162026. Annual cost of therapy ACOT and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting NASH therapeutics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative earlystage projects, and detailed analysis of latestage pipeline products.
Analysis of the current and future market competition in the global NASH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to
Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NASH therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Original Article: OpportunityAnalyzer: NASH Opportunity Analysis and Forecasts to 2026 [Report Updated: 08052017] Prices from USD $10995

NEXT ARTICLE

More From BioPortfolio on "OpportunityAnalyzer: NASH Opportunity Analysis and Forecasts to 2026 [Report Updated: 08052017] Prices from USD $10995"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...